AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6666218
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (initial dose of 40 mg orally)
Trial: 6666218
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral isosorbide dinitrate (40 mg every 6 h)
Trial: 29542262
Drug: Intensive counseling,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive counseling, pharmacotherapy, text‐messaging, and financial incentives
Trial: 22956863
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg PBE supplementation once daily
Trial: 22956863
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg PBE supplementation once daily
Trial: 17532750
Drug: MMF dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF dose, MPA‐AUC, and the 2 h AUCs of MPAG and AcMPAG
Trial: 3347071
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of diphenhydramine and 300 mg of cimetidine
Trial: 27618657
Drug: Pancreatic exocrine
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic exocrine replacement therapy (PERT) consisting of 6-9 capsules of pancreatin (457.7 mg/capsule), taken two capsules three times daily during main meals and one capsule up to three times daily for snacks
Trial: 22486159
Drug: Crushed lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crushed lisinopril
Trial: 12419743
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (FEC: fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2))
Trial: 12419743
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (FEC)
Trial: 7582281
Drug: salbutamol and
RxNorm normalized name: salbutamol and budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol and budesonide combination
Trial: 27998620
Drug: Tocilizumab, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab, an interleukin‐6 receptor‐alpha inhibitor
Trial: 25917295
Drug: Intensive Short-Term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Short-Term Dynamic (ISTDP) residential treatment program
Trial: 25917295
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (wait-list control)
Trial: 19524334
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) with agalsidase alpha or agalsidase beta
Trial: 15994387
Drug: montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: montelukast 10 mg q.d.
Trial: 12568841
Drug: Immediate oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate oral contraceptive start
Trial: 12568841
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral contraceptive start
Trial: 1757831
Drug: Endotracheal suction
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotracheal suction with saline instillation (0.25-0.5 ml)
Trial: 6624697
Drug: alpha‐tocopherol supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐tocopherol supplement of 800 IU
Trial: 6624697
Drug: beta‐carotene supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐carotene supplement of 30 mg (5000 retinol equivalents)
Trial: 6624697
Drug: retinyl palmitate
RxNorm normalized name: Retinyl palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: retinyl palmitate supplement of 25,000 IU (13,750 retinol equivalents)
Trial: 23747131
Drug: Concomitant therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy: omeprazole 20mg, amoxicillin 1g, clarithromycin 500 mg, and tinidazole 500 mg for 5 days
Trial: 23747131
Drug: Sequential therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy: omeprazole 20mg and amoxicillin 1g for 5 days followed by omeprazole 20mg, clarithromycin 500 mg, and tinidazole 500 mg for 5 days
Trial: 23747131
Drug: Hybrid therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid therapy: omeprazole 20mg, and amoxicillin 1g for 7 days followed by omeprazole 20mg, amoxicillin 1g, clarithromycin 500 mg, and tinidazole 500 mg for 7 days
Trial: 23747131
Drug: Second-line therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line therapy: omeprazole 20mg, levofloxacin 250 mg, and amoxicillin 1g, all given twice daily for 10 days
Trial: 20665553
Drug: Open-label treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label treatment
Trial: 19722254
Drug: 3,4-Diaminopyridine (DAP)
DrugBank: Amifampridine (DB11640)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3,4-Diaminopyridine (DAP) up to 75-80 mg/day
Trial: 12131981
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (mentholated deionized water)
Trial: 10613374
Drug: Tablet splitting
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet splitting using a tablet splitter
Trial: 10613374
Drug: Tablet splitting
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet splitting
Trial: 1747217
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of elemental calcium in the form of oystershell electrolysate (AA calcium)
Trial: 6186187
Drug: Levamisole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (2.5 mg/kg/dose)
Trial: 24679444
Drug: IAI 2
RxNorm normalized name: Intravitreal aflibercept injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAI 2 mg (IAI 2Q4)
Trial: 20060571
Drug: Road traffic
RxNorm normalized name: Road to Wellness KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Road traffic noise exposure (n=280, L(eq,24h)=67±2dB(A))
Trial: 20060571
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=379, L(eq,24h)=58.7±6dB(A))
Trial: 17546842
Drug: Flaxseed flour
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed flour (30 g/day, 5 g of alpha-linolenic acid)
Trial: 12058009
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment initiated in early adolescence
Trial: 12058009
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment initiated in later adolescence
Trial: 8577212
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg o.a.d.
Trial: 8577212
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.i.d.
Trial: 8577212
Drug: Lansoprazole 45
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 45 mg b.i.d.
Trial: 8577212
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg b.i.d.
Trial: 2225893
Drug: Paste without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paste without antibiotics applied to the oropharynx (Control group).
Trial: 371057
Drug: Clemastine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine, 1 mg/ml
Trial: 24444658
Drug: Daclatasvir (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) twice-daily (DUAL A1)
Trial: 24444658
Drug: Daclatasvir (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) once-daily (DUAL A2)
Trial: 24444658
Drug: Daclatasvir (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) twice-daily + PegIFN/RBV (QUAD B1)
Trial: 24444658
Drug: Daclatasvir (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (60 mg) once-daily + asunaprevir (200 mg) once-daily + PegIFN/RBV (QUAD B2)
Trial: 24444658
Drug: Asunaprevir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asunaprevir (200 mg) twice-daily + ribavirin (TRIPLE B3)
Trial: 20063238
Drug: Zestra (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zestra (topical botanical preparation)
Trial: 18280328
Drug: Six doses
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six doses of activated charcoal (50 g each at 4-hour intervals)
Trial: 18280328
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of activated charcoal (50 g)
Trial: 12687557
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg body weight) at weeks 0, 2, and 6
Trial: 8545692
Drug: Bolus fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus fluid therapy
Trial: 1878583
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX: 12 g/m2 as 4-hour infusion)
Trial: 1878583
Drug: Intermediate-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose methotrexate (IDMTX: 1 g/m2 as 36-hour infusion)
Trial: 1878583
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with daily oral thioguanine and biweekly intravenous (IV) MTX
Trial: 6617676
Drug: Hydralazine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (mean 127 mg/day, range 37-225)
Trial: 29889597
Drug: Brain-targeted treatment
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain-targeted treatment (BT) phase (left/right judgments and touch discrimination training)
Trial: 29889597
Drug: No-treatment phase
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment phase
Trial: 15965311
Drug: LY450139 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY450139 (50 mg/day for 14 days)
Trial: 15965311
Drug: LY450139 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY450139 (5 mg, 20 mg, 40 mg doses)
Trial: 15965311
Drug: LY450139 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY450139 (50 mg/day)
Trial: 15965311
Drug: LY450139 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY450139 (all doses)
Trial: 11086589
Drug: Arizona Pilot
RxNorm normalized name: Arizona ash pollen extract
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arizona Pilot Project treatment (capitation)
Trial: 11086589
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment administration sites
Trial: 9071904
Drug: Fenretinide (4-HPR)
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide (4-HPR) 200 mg/day
Trial: 7690396
Drug: Granulocyte-colony stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony stimulating factor (G-CSF) 5 micrograms/Kg/day
Trial: 31880804
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) added to standard front-line chemotherapy
Trial: 28012706
Drug: Methylphenidate (30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (30mg single dose)
Trial: 21823414
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Carbamazepine)
Trial: 17262141
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - no treatment (G6)
Trial: 14586718
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (23 patients)
Trial: 8459060
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (8.0 +/- 2.0 mg/liter)
Trial: 30282349
Drug: Core stability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core stability exercises in addition to traditional treatment (infrared radiation and continuous ultrasound)
Trial: 30282349
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (infrared radiation and continuous ultrasound)
Trial: 30282349
Drug: Core stability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core stability exercises in addition to traditional treatment
Trial: 29185931
Drug: J‐aggregated zeaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: J‐aggregated zeaxanthin dipalmitate formulation (10 mg free zeaxanthin)
Trial: 29185931
Drug: H‐aggregated zeaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H‐aggregated zeaxanthin dipalmitate formulation (10 mg free zeaxanthin)
Trial: 26109247
Drug: PEERS program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEERS program (treatment group, n = 12)
Trial: 26109247
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment control (control group, n = 10)
Trial: 22264206
Drug: Individualized oral
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized oral instruction
Trial: 22264206
Drug: Standardized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized oral instruction
Trial: 17524880
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril (E) 10 mg/d, 15 patients
Trial: 17524880
Drug: Losartan (L)
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan (L) 50 mg/d, 20 patients
Trial: 17524880
Drug: Enalapril +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril + Losartan (E+L) 10 mg/d + 50 mg/d, 13 patients
Trial: 17524880
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication), 22 patients
Trial: 2796623
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 20 mL of 2% lidocaine + 3 mL normal saline
Trial: 2796623
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 20 mL of 2% lidocaine + 1:200000 epinephrine + 5 mL normal saline
Trial: 2796623
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 20 mL of 2% lidocaine + 2 mL of fentanyl + 3 mL normal saline
Trial: 2796623
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: 20 mL of 2% lidocaine + 5 mL normal saline
Trial: 266502
Drug: Monthly professional
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly professional mechanical tooth cleaning
Trial: 29851985
Drug: RBV (Ribavirin)
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RBV (Ribavirin) in combination with ombitasvir/paritaprevir/ritonavir and dasabuvir
Trial: 29851985
Drug: DAA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAA treatment (ombitasvir/paritaprevir/ritonavir and dasabuvir)
Trial: 27029846
Drug: Elvitegravir (reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elvitegravir (reduced dose of 85 mg) co-administered with cobicistat and atazanavir
Trial: 17629069
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg) thrice daily for 4 weeks
Trial: 15059101
Drug: Oral nickel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nickel exposure (4 mg)
Trial: 11454246
Drug: Annual mass
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual mass treatment with single-dose diethylcarbamazine plus ivermectin
Trial: 11454246
Drug: Annual mass
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual mass treatment with single-dose diethylcarbamazine plus ivermectin plus vector control
Trial: 9736230
Drug: Calcium polycarbophil
RxNorm normalized name: Calcium Polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium polycarbophil (0.62 g/twice daily)
Trial: 7988625
Drug: Transnasal butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transnasal butorphanol (1 mg)
Trial: 7988625
Drug: Intravenous butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous butorphanol (1 mg)
Trial: 7988625
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and transnasal administration
Trial: 2919094
Drug: Antiprostaglandin agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiprostaglandin agents (naproxen)
Trial: 2919094
Drug: Antiprostaglandin agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiprostaglandin agents (pirprofen)
Trial: 2919094
Drug: Antiprostaglandin agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiprostaglandin agents (active treatment)
Trial: 29017595
Drug: Locally produced
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally produced enalapril (5-20 mg once daily for 14 days)
Trial: 29017595
Drug: Imported enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported enalapril (5-20 mg once daily for 14 days)
Trial: 15800157
Drug: Antidepressant plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant plus olanzapine
Trial: 1742537
Drug: Resumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resumption of interferon at the same dosage after relapse
Trial: 7201436
Drug: Argon laser
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon laser treatment for pigment epithelial detachments (6 eyes)
Trial: 7201436
Drug: Argon laser
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon laser treatment for subretinal neovascular membranes (7 eyes)
Trial: 28573743
Drug: Ixekizumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (80 mg as one injection every 4 weeks)
Trial: 28573743
Drug: Ixekizumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (80 mg as one injection every 2 weeks)
Trial: 25080876
Drug: IA clodronate
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA clodronate 2 mg
Trial: 19459829
Drug: 10-mg metoclopramide
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg metoclopramide ODT
Trial: 19459829
Drug: Conventional 10-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 10-mg metoclopramide tablet
Trial: 17470680
Drug: Capecitabine in
RxNorm normalized name: Product containing capecitabine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine in combination with lapatinib
Trial: 17470680
Drug: Capecitabine in
RxNorm normalized name: Product containing capecitabine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine in combination with trastuzumab
Trial: 17470680
Drug: Capecitabine in
RxNorm normalized name: Product containing capecitabine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine in combination with bevacizumab
Trial: 9693891
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral gastroscopy
Trial: 7943066
Drug: Amnioinfusion (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amnioinfusion (800 ml bolus of normal saline followed by continuous infusion at 180 ml/hr)
Trial: 3211167
Drug: Aminophyllin treatment
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophyllin treatment administered orally for one week
Trial: 3211167
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no aminophyllin treatment)